{"filings":[{"id":69481,"accession_number":"0001437749-26-016760","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2026-05-13T20:41:28+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva Q1 net loss $3.2M; stock moving from Nasdaq to OTCQB effective May 14","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M ($0.46/share) vs $6.4M ($2.61) in Q1 2025; cash $22.2M up from $14.4M.","Completed public equity offering raising $10M gross in March 2026.","Filed provisional patent for new brilaroxazine form to extend exclusivity through 2046; FDA feedback expected mid-2026.","RECOVER-2 Phase 3 schizophrenia trial enrollment planned for Q3 2026.","Common stock to stop trading on Nasdaq and move to OTCQB on May 14, 2026, under symbol RVPH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50401,"accession_number":"0001437749-26-016538","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2026-05-13T12:03:45+00:00","items":["3.01","8.01"],"status":"ready","headline":"Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Hearings Panel determined to delist RVPH due to non-compliance with minimum $1.00 bid price rule.","Trading on Nasdaq suspended as of May 14, 2026; stock will quote on OTCQB Venture Market under same symbol RVPH.","Delisting risks include reduced liquidity, fewer investors, penny stock classification, and limited analyst coverage.","Company updated risk factors to reflect additional risks of OTC trading vs. national exchange listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95124,"accession_number":"0001437749-26-012303","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva targets brilaroxazine patent extension to 2046, plans API switch in RECOVER-2 trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed composition of matter patent on new brilaroxazine form; pursuing accelerated review to extend exclusivity potentially through 2046.","Preparing to seek FDA alignment to switch API and formulation in RECOVER-2; feedback expected mid-2026.","RECOVER-2 trial activities start Q2 2026, patient enrollment Q3 2026, completion expected Q4 2027.","Closed $10M financing on March 20, 2026; pro forma cash ~$23M, expected to fund operations into Q1 2027.","Evaluating strategic alternatives to maximize brilaroxazine value; recent reverse stock split and financing were difficult but necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107970,"accession_number":"0001437749-26-010140","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva reports FY2025 net loss of $19.9M; FDA requires second Phase 3 trial for schizophrenia drug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.9M ($5.48 per share) vs $29.9M ($17.73) in FY2024.","Cash and equivalents $14.4M at Dec 31, 2025; ~$23M after March 2026 offering, funding into Q1-2027.","FDA recommended a second Phase 3 trial (RECOVER-2) for brilaroxazine in schizophrenia; initiation planned mid-2026.","Positive 1-year open-label extension data: sustained efficacy, benign weight gain (~1.5 kg), no motor side effects.","Completed public offerings totaling $29M in 2025 and early 2026; intends to fund RECOVER-2 trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107969,"accession_number":"0001437749-26-009063","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals announces $10M public offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 6,666,667 shares (or pre-funded warrants) plus Series G and H warrants at $1.50/unit; gross proceeds $10M.","Series G warrants exercisable at $1.50 for 5 years; Series H warrants exercisable at $1.50 for 1 year.","Net proceeds ~$9M to fund RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia and for working capital.","Closing expected March 20, 2026; A.G.P./Alliance Global Partners acting as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107968,"accession_number":"0001437749-26-006991","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Reviva Pharma announces 1:20 reverse stock split to regain Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Reverse stock split at 1:20 ratio effective 12:01 a.m. ET on March 9, 2026; no fractional shares, rounding up.","Nasdaq Staff granted an exception to demonstrate compliance with $1 bid price requirement through March 27, 2026.","Company received delisting notice in Nov 2025; hearing held Jan 8, 2026; exception granted.","If compliance not regained, stock may be delisted, harming liquidity and capital access.","CUSIP changes to 76152G 209; trading symbol remains RVPH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107967,"accession_number":"0001437749-26-001913","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Reviva gets Nasdaq extension to March 27, 2026 for minimum bid price rule compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq Panel granted exception through March 27, 2026 to regain compliance with $1.00 minimum bid price.","Company requested hearing after delisting determination on Nov 11, 2025; hearing held Jan 8, 2026.","To regain compliance, closing bid price must be at least $1.00 for 10 consecutive business days.","Company may implement reverse stock split if needed; warns split may not maintain price increase.","Risk of delisting remains if unable to meet deadline or other Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124380,"accession_number":"0001437749-25-038602","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.03","5.07","7.01","8.01","9.01"],"status":"ready","headline":"FDA requires second Phase 3 trial for Reviva's brilaroxazine in schizophrenia; NDA delayed to late 2027","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA recommends RECOVER-2 Phase 3 trial (30/50 mg) before NDA submission; similar to RECOVER design.","RECOVER-2 initiation planned H1 2026, data Q2 2027; NDA target Q4 2027, potential approval Q4 2028; est. cost ~$60M.","Stockholders approved authorized share increase from 315M to 515M and reverse stock split (1:2 to 1:20, Board discretion).","Warrant exercises Oct–Dec 2025: 19.8M shares, ~$6.7M net; cash ~$14.7M as of Dec 16, sufficient through Q2 2026 ex-RECOVER-2.","Long-term safety data from RECOVER open-label extension over 52 weeks shows favorable tolerability and adherence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124379,"accession_number":"0001437749-25-034846","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva reports Q3 net loss of $4.0M; cash $13.2M; pre-NDA meeting with FDA on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.0M ($0.06 per share) for Q3 2025, compared to $8.4M ($0.25) in Q3 2024.","Cash and cash equivalents totaled $13.2M as of September 30, 2025.","Pre-NDA meeting with FDA planned for Q4 2025; NDA submission for schizophrenia targeted for Q2 2026.","European patent granted covering use of brilaroxazine for treatment of pulmonary fibrosis.","Closed public equity offering with gross proceeds of $9.0M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124378,"accession_number":"0001437749-25-031278","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Reviva regains Nasdaq MVLS compliance; still faces bid price delisting risk by Nov 10","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Oct 14 confirming compliance with $35M minimum market value of listed securities requirement; matter closed.","Remains non-compliant with $1.00 minimum bid price rule; initial cure period ends November 10, 2025.","May consider reverse stock split to regain bid price compliance; no assurance of success.","Previous MVLS non-compliance resolved after 10 consecutive business days above $35M (Sept 30 to Oct 13)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141058,"accession_number":"0001437749-25-029951","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals reduces stockholder meeting quorum to 33⅓% of voting power","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted quorum reduction from majority to one-third (33⅓%) of outstanding voting stock.","Amendment effective September 26, 2025; applies to all stockholder meetings unless law or charter requires higher.","Previous Bylaws required a majority of shares entitled to vote in person or by proxy.","No other changes to the Bylaws were made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141057,"accession_number":"0001437749-25-029531","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Reviva prices $9M public offering of 27M shares and warrants at $0.335/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["27M shares of common stock plus Series E (5-year term) and Series F (1-year term) warrants, each exercisable for 27M shares at $0.335.","Gross proceeds of $9M; net proceeds ~$8.1M after fees and expenses.","Offering expected to close on or about September 22, 2025, subject to customary conditions.","Proceeds to fund R&D activities and for working capital and general corporate purposes.","Placement agent: A.G.P./Alliance Global Partners; securities offered under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141056,"accession_number":"0001437749-25-026971","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva Q2 2025 net loss $6.1M ($0.12/share); cash $10.4M; brilaroxazine OLE data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.1M vs $7.9M YoY; cash $10.4M as of June 30, 2025, down from $13.5M at Dec 2024.","Completed Phase 3 RECOVER OLE 1-year trial: brilaroxazine sustained PANSS total score -18.1 over 1 year.","FDA meeting planned Q4 2025 for path to approval; potential NDA submission targeted Q2 2026.","Completed $10.0M public equity offering in Q2 2025.","Plans to assess registrational Phase 3 RECOVER-2 pending FDA feedback; IND for psoriasis formulation expected Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158844,"accession_number":"0001437749-25-021361","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Reviva prices $10M public offering of 20M shares and warrants at $0.50 per unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering comprises 20M shares, 20M Series C warrants (5-year, $0.50 exercise), and 20M Series D warrants (12-month, $0.50 exercise).","Gross proceeds of $10M; net proceeds expected ~$9.0M after fees.","Net proceeds to fund R&D, working capital, and general corporate purposes.","Closing expected June 27, 2025; 60-day lock-up on share issuance and one-year variable rate transaction restriction.","A.G.P./Alliance Global Partners serving as sole placement agent with 7.0% cash fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158843,"accession_number":"0001437749-25-019716","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals appoints Baker Tilly as new auditor after Moss Adams merger","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Moss Adams LLP merged with Baker Tilly US, LLP effective June 3, 2025; Moss Adams resigned as auditor the same day.","Audit Committee appointed Baker Tilly as successor independent registered public accounting firm effective June 3, 2025.","No disagreements or reportable events occurred with Moss Adams during fiscal years 2024-2025 interim period.","Prior audit reports included a going concern explanatory paragraph; no adverse or qualified opinions issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158842,"accession_number":"0001437749-25-019062","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva reports positive full dataset from Phase 3 OLE study of brilaroxazine in schizophrenia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Brilaroxazine showed sustained efficacy across all symptom domains: PANSS total score improved -18.1 at 12 months (p≤0.001).","Safety profile well-tolerated: 8.5% TEAEs mostly mild, no drug-related SAEs; discontinuation rate 35%.","Mild weight gain (1.52 kg) and no clinically significant cardiac, liver, or metabolic side effects.","Long-term safety data from 100 patients completing 1 year meets NDA submission requirement for FDA.","Improved multiple neuroinflammatory biomarkers; virtual webcast held June 2, 2025 at 8:00 a.m. EDT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158841,"accession_number":"0001437749-25-018972","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals enters into ATM sales agreement for up to $50M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On May 30, 2025, Reviva entered an ATM agreement with B. Riley Securities and Alliance Global Partners to sell up to $50M of common stock.","Sales will be made through Nasdaq as an 'at the market offering' under Rule 415; agents receive 3% commission.","Shares issued under effective shelf registration statement (Form S-3 filed Feb 2024).","No obligation for agents to sell any specific amount; they use commercially reasonable efforts based on company instructions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158840,"accession_number":"0001437749-25-017185","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva Q1 2025 net loss $6.4M; cash $5.3M; OLE trial complete with 446 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.4M ($0.13/sh) vs $7.4M ($0.25/sh) in Q1 2024; cash & equivalents $5.3M as of Mar 31, 2025 down from $13.5M at Dec 31, 2024.","Long-term OLE trial of brilaroxazine completed: 446 participants, 156 completed 12 months, 301 completed 6 months.","Full OLE data (safety, efficacy, biomarkers) expected Q2 2025; registrational Phase 3 RECOVER-2 initiation expected mid-2025 subject to financing.","NDA submission for brilaroxazine in schizophrenia targeted for Q4 2026; IND for psoriasis liposomal-gel formulation expected later in 2025.","Company to present late-breaking poster on RECOVER 12-month OLE data at ASCP meeting on May 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177248,"accession_number":"0001437749-25-010191","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva reports FY2024 net loss $29.9M, cash $13.5M; positive OLE data sustained","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.9M ($0.90/shr) vs $39.3M ($1.65/shr) in 2023; cash $13.5M at Dec 31, 2024 vs $23.4M.","OLE trial: pooled PANSS total score decreased 18.6 points (p≤0.0001) at 1 year; well tolerated with no single side effect >5%.","Registrational Phase 3 RECOVER-2 trial for brilaroxazine in schizophrenia expected to initiate mid-2025.","Full OLE data including vocal and blood biomarkers due Q2 2025; NDA submission targeted Q4 2026.","Completed public follow-on offering with gross proceeds of ~$18.0M in December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177247,"accession_number":"0001437749-25-004224","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reviva Pharmaceuticals adjusts exec compensation; CEO salary $565k, options at $1.80","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Bhat base salary to $565k; CFO Prabhu $330k; VP Bhat $340k, effective retroactive Jan 1, 2025.","2024 cash bonuses: Dr. Bhat $157,500; Mr. Prabhu $79,950; Ms. Bhat $77,500.","2025 bonus targets: 50% of base (CEO), 41% (CFO), 32% (VP), subject to Compensation Committee criteria.","Option grants at $1.80 strike: CEO 519k shares, CFO 194.25k, VP 181.5k; ~42% vested immediately, rest monthly through Dec 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194014,"accession_number":"0001437749-24-037764","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Reviva prices $18M public offering of 12M shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 12M shares of common stock plus Series A warrants (6M shares, 6-month term) and Series B warrants (12M shares, 5-year term) at $1.50/unit.","Gross proceeds $18M; net proceeds ~$15.8M after underwriting discounts and expenses.","Series A warrants exercisable at $1.50, expire in 6 months; Series B warrants at $1.50, expire in 5 years.","Expected closing on December 18, 2024; Citizens JMP Securities is sole bookrunner.","Proceeds to fund R&D, working capital, and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194013,"accession_number":"0001437749-24-037520","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva reports positive preliminary 1-year OLE data for brilaroxazine in schizophrenia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["435 patients enrolled in OLE; 113 completed 52 weeks; pooled PANSS total decreased 18.6 points (p≤0.0001).","Dose-dependent efficacy: PANSS total decreases of -15.2, -18.6, -20.8 for 15, 30, 50 mg doses.","Safety: 15.2% TRAE, mostly mild; no drug-related SAEs; discontinuation rate 35%, primarily withdrawal of consent (22%).","Long-term safety data from 100+ patients meets FDA NDA submission requirement; full OLE data expected Q1 2025.","Brilaroxazine generally well-tolerated with no single side effect >5%; no clinically meaningful movement disorder changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194012,"accession_number":"0001437749-24-037373","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-12-12T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Reviva shareholders approve increase in authorized common stock from 115M to 315M; all director nominees elected.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased to 315M from 115M, effective December 10, 2024.","All five director nominees (Bhat, Saxena, Margolin, Patel, Funtleyder) elected.","Ratification of Moss Adams as auditor approved with 20.8M for, 1.7M against.","Advisory say-on-pay approved (6.7M for); board set future advisory votes annually.","Adjournment proposal not needed as share increase vote had sufficient votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194011,"accession_number":"0001437749-24-035391","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva Q3 net loss $8.4M; 108 patients complete 1-year OLE trial for brilaroxazine","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.4M ($0.25/sh) for Q3 2024 vs $11.3M ($0.48/sh) in Q3 2023 (restated).","Cash totaled $5.6M as of Sep 30, 2024, down from $23.4M at Dec 31, 2023.","108 patients have completed 1 year of treatment in brilaroxazine OLE trial; topline data expected December 2024.","NDA submission for brilaroxazine in schizophrenia targeted for Q2 2026; RECOVER-2 start expected Q1 2025 pending financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194010,"accession_number":"0001437749-24-034338","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva: 108 patients complete 1-year brilaroxazine OLE; topline data expected Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["108 patients completed 12-month treatment; over 250 completed 6 months in the OLE study.","Long-term safety data from 100 patients with 12 months treatment now available for planned NDA submission.","Brilaroxazine continues to be generally well tolerated in acute and stable schizophrenia patients.","Topline 12-month long-term safety and efficacy data expected in December 2024.","OLE study (RECOVER) completion anticipated in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210351,"accession_number":"0001437749-24-029392","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-09-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Reviva awards FY2023 bonuses: CEO $157,500, CFO $95,940, VP $77,376 in options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2023 incentive bonuses for named executive officers paid as immediately vested stock options in lieu of cash.","CEO Laxminarayan Bhat granted 158,451 options at $1.20 per share; bonus value $157,500.","CFO Narayan Prabhu granted 96,519 options at $1.20 per share; bonus value $95,940.","VP Seema Bhat granted 77,843 options at $1.20 per share; bonus value $77,376."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210347,"accession_number":"0001437749-24-027621","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K/A","filed_at":"2024-08-22T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals raises $3.8M net in public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds from offering updated to $3.8M; closed Aug 22, 2024.","Sold 3,276,262 shares at $1.05/share along with warrants to purchase up to 4,761,905 shares at $0.7964.","Also issued pre-funded warrants for 1,485,643 shares and underwriter warrants for 238,095 shares at $1.3125.","Existing warrants from 2021 and 2023 amended: exercise price lowered to $0.7964, expiration extended to 5 years.","Titan Partners Group underwriter; 8.0% commission and expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210350,"accession_number":"0001437749-24-027511","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-08-21T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Reviva prices $5.0M at-the-market offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering comprises 4,761,905 shares (or pre-funded warrants) plus warrants for same number; combined price $1.05 per unit.","Warrants exercisable at $0.7964/share, expire 5 years from issuance; pre-funded warrants at $0.0001/share.","Existing warrants for up to 4,736,561 shares amended to $0.7964 exercise price and 5-year term for $0.125 per warrant.","Net proceeds expected to fund Phase 3 RECOVER-2 trial and working capital; gross proceeds ~$5.0M.","Titan Partners Group is sole bookrunner; closing expected August 22, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210349,"accession_number":"0001437749-24-026567","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva Q2 2024 net loss $7.9M; cash $6.2M; OLE topline data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.9M ($0.26/sh) vs $11.7M ($0.52/sh) in Q2 2023; six-month loss $15.3M ($0.51/sh).","Cash $6.2M at June 30, 2024, down from $23.4M at Dec 31, 2023.","Topline data from 1-year OLE trial in schizophrenia expected Q4 2024; registrational RECOVER-2 trial to start Q3 2024.","U.S. patent granted for brilaroxazine in IPF; European patent for pulmonary hypertension; both received Orphan Drug Designation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210348,"accession_number":"0001437749-24-022354","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"European patent granted covering brilaroxazine for pulmonary hypertension; adds to US, China, Japan patents","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Patent EP3244896 granted covering brilaroxazine for treating PH, PAH, including PH in COPD or SCD patients.","Similar patents already granted in United States, China, and Japan for brilaroxazine in PH/PAH.","Brilaroxazine has Orphan Drug Designation from FDA for treatment of pulmonary arterial hypertension.","CEO cites anti-inflammatory/antifibrotic activity in animal models; plans to evaluate PH/PAH expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228665,"accession_number":"0001437749-24-018540","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Reviva announces $3M registered direct offering of 1.9M shares and warrants at $1.58/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 1,898,734 shares and warrants at $1.58/unit; warrants exercisable at $1.455 for 5 years.","Net proceeds ~$3.0M; funds Phase 3 RECOVER-2 trial and working capital.","Existing Nov 2023 warrants (1,365,854 shares, $5.00 exercise) amended to $1.455, extended 5 years.","H.C. Wainwright placement agent; cash fee 6% of gross proceeds.","Closing expected May 29, 2024, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228664,"accession_number":"0001437749-24-016796","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva updates RECOVER OLE enrollment: 358 enrolled, 23 completed 12 months, NDA on track for Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["358 patients enrolled; 223 currently on treatment across USA, Europe, and Asia.","23 patients have completed 12 months of treatment; targeting 100 for NDA submission.","Brilaroxazine generally well tolerated in acute and stable schizophrenia patients.","Topline 12-month safety data expected in Q4 2024; NDA submission planned for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228663,"accession_number":"0001437749-24-016364","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva Q1 net loss $7.4M; FDA alignment on brilaroxazine NDA path","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss approximately $7.4M ($0.25 per share) for Q1 2024 vs $6.9M ($0.31 per share) for Q1 2023.","Cash $12.0M as of March 31, 2024, down from $23.4M at December 31, 2023.","FDA aligned on registrational Phase 3 program for brilaroxazine in schizophrenia; RECOVER-2 trial start expected Q2 2024.","Topline data from 1-year OLE trial expected Q4 2024; potential NDA submission targeted for Q4 2025.","Company initiated Phase 3 RECOVER-1 data presentations at SIRS and ASCPT meetings in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228662,"accession_number":"0001437749-24-012074","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva gains FDA alignment on Phase 3 RECOVER-2 study for brilaroxazine in schizophrenia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepts 4-week RECOVER-2 study; two positive Phase 3 studies plus 12-month safety could support NDA.","Topline data from 1-year OLE long-term safety trial expected Q4 2024; NDA submission targeted by Q3 2025.","RECOVER-2 is a 450-patient global Phase 3 trial; primary endpoint is PANSS total score change at Day 28.","Company plans to initiate first clinical site in Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228661,"accession_number":"0001437749-24-011953","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva FY2023 net loss $39.3M; restates 2022; positive Phase 3 schizophrenia data; RECOVER-2 trial planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $39.3M ($1.65/sh) for FY2023 vs restated $28.3M ($1.45/sh) for FY2022.","Cash $23.4M as of Dec 31, 2023; completed $30M registered direct offering in Nov 2023.","Restated FY2022 results due to ~$3.9M under-accrual of clinical trial expenses.","Phase 3 RECOVER-1 met primary endpoint: 10.1-point PANSS reduction at 50mg vs placebo (p<0.001).","Registrational RECOVER-2 trial starts Q2 2024; NDA submission for brilaroxazine targeted Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228660,"accession_number":"0001437749-24-011948","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2024-04-15T23:59:59+00:00","items":["2.02","4.02"],"status":"ready","headline":"Reviva Pharmaceuticals to restate 2022 and 2023 financials; R&D expenses understated by ~$3.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee concluded prior financials for FY2022, Q3 2022, and all quarterly periods in FY2023 should no longer be relied upon due to errors in clinical trial expense accruals.","FY2022 R&D expenses understated by approximately $3.9 million; net loss understated by same amount.","Material weaknesses identified in internal controls over financial reporting related to clinical trial expense accruals and insufficient resources.","Company expects to file restated financials in comprehensive 2023 10-K within 12b-25 extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264753,"accession_number":"0001437749-23-032463","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-11-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Reviva raises $30M in registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,853,660 shares (or pre-funded warrants) and 5,853,660 warrants at $5.125 per unit.","Warrants exercisable at $5.00 per share, expire 5 years from issuance.","Net proceeds expected ~$27.9M; director affiliate purchased $3M in pre-funded warrants.","Proceeds to fund registrational Phase 3 RECOVER-2 trial and other R&D activities.","Closing expected on or about November 20, 2023, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264752,"accession_number":"0001437749-23-031981","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Reviva shareholders elect all five director nominees and ratify Moss Adams as auditor at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected: Laxminarayan Bhat, Parag Saxena, Richard Margolin, Purav Patel, Les Funtleyder.","Votes for director nominees ranged from 7,991,179 to 8,713,962; broker non-votes of 5,873,081 on each.","Ratification of Moss Adams LLP as auditor approved: 14,574,768 for, 11,880 against, 9,917 abstentions.","Meeting held November 13, 2023; results filed under Item 5.07."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264751,"accession_number":"0001437749-23-031971","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva reports Q3 loss of $10.5M; Phase 3 brilaroxazine trial meets all endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Phase 3 RECOVER trial met primary endpoint: 10.1-point PANSS reduction for 50 mg brilaroxazine vs placebo at week 4 (p<0.001).","Net loss for Q3 2023 of $10.5M ($0.44/share) vs $3.5M loss ($0.18/share) in Q3 2022.","Cash of $5.0M as of Sep 30, 2023, down from $18.5M at Dec 31, 2022.","Anticipated milestones: OLE data Q4 2024; RECOVER-2 initiation Q1 2024; NDA submission 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264748,"accession_number":"0001437749-23-031978","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K/A","filed_at":"2023-11-14T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals completes auditor change to Moss Adams LLP effective Nov 14, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Armanino LLP's engagement ended Nov 14, 2023 after completing Q3 2023 review; Moss Adams LLP engaged same day.","Armanino's 2022 audit report included a going concern explanatory paragraph; no disagreements or reportable events.","Moss Adams was not consulted on accounting principles or audit opinion prior to engagement.","Auditor change previously disclosed Oct 4, 2023; this amendment adds effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264750,"accession_number":"0001437749-23-029310","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-10-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva announces positive Phase 3 RECOVER trial results for brilaroxazine in schizophrenia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: brilaroxazine 50 mg showed 10.1-point PANSS reduction vs placebo (p<0.001) at week 4.","Statistically significant improvements in all major symptom domains and secondary endpoints at 50 mg dose.","Well-tolerated with no drug-related SAEs; discontinuation rates lower than placebo (16% vs 22%).","Plans to report OLE topline data in Q4 2024 and initiate Phase 3 RECOVER-2 in Q1 2024; NDA submission expected 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264749,"accession_number":"0001437749-23-027674","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals appoints Moss Adams as new auditor after Armanino's exit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee appointed Moss Adams LLP as independent accountant for fiscal year ending Dec 31, 2023 on Oct 4, 2023.","Armanino LLP declines reappointment due to transition away from public company audits; notified company on July 18, 2023.","Armanino's audit reports for 2021 and 2022 contained no adverse opinions; 2022 report included a going concern paragraph.","No disagreements or reportable events occurred during Armanino's tenure through Oct 4, 2023.","Armanino remains engaged to complete review of Q3 2023 unaudited financial statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281972,"accession_number":"0001437749-23-023999","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva completes enrollment in Phase 3 RECOVER study for brilaroxazine in schizophrenia; topline data expected Oct 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment of 402 patients across US (~60%), Europe (~10%), and Asia (~30%) in pivotal Phase 3 RECOVER trial.","Topline efficacy and safety data for RECOVER expected in October 2023.","Over 50% of patients enrolled in 1-year open-label extension study; completion expected in Q3 2024.","Primary endpoint: change in PANSS total score from baseline to Day 28 vs placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281971,"accession_number":"0001437749-23-023680","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva Q2 net loss $12.4M; cash $11.2M; Phase 3 schizophrenia data due Oct 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.4M ($0.55 per share) for Q2 2023 vs $5.3M ($0.29) a year ago.","Cash $11.2M as of June 30, 2023, down from $18.5M at Dec 2022; runway into Q4 2023.","Topline data for pivotal Phase 3 RECOVER trial of brilaroxazine in schizophrenia expected October 2023.","Enrollment near completion (~400 patients); 1-year OLE study completion expected Q3 2024.","May initiate Phase 2a studies in bipolar, MDD, ADHD in H2 2023 subject to additional financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281970,"accession_number":"0001437749-23-020536","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals' auditor Armanino declines re-appointment; audit committee seeks new firm","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Armanino LLP notified Reviva on July 18, 2023 it will not stand for re-appointment after Q3 2023 review.","Reason: Armanino is transitioning away from providing audit services to public companies.","Audit reports for FY2021 and FY2022 were unqualified; FY2022 included a going-concern paragraph.","No disagreements or reportable events occurred during the period through July 18, 2023.","Audit committee has begun search for a new independent registered public accountant for FY2023 audit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300994,"accession_number":"0001437749-23-018164","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Reviva Pharmaceuticals: Phase 3 RECOVER study enrollment exceeds 80%; topline data expected Q3 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 80% of patients enrolled in pivotal Phase 3 RECOVER study of brilaroxazine for schizophrenia; enrollment ongoing in US, Europe, Asia.","Topline data from the ~400-patient placebo-controlled trial expected in Q3 2023.","Company also reports $5.7M in gross proceeds from Q2 2023 warrant exercises: $4.74M from common warrants at $2.40/share and $0.915M from investor warrants at $4.125/share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300993,"accession_number":"0001437749-23-014572","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva Q1 net loss $6.6M; cash to fund ops through Q3 2023; Phase 3 topline data mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.6M ($0.30/shr) vs $7.4M ($0.40) in Q1 2022; cash $11.3M at Mar 31, 2023, down from $18.5M.","Cash sufficient to fund current plans through Q3 2023; additional financing needed for Phase 2a studies.","Over 60% of ~400 patients enrolled in Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.","Brilaroxazine lipogel showed proof-of-concept in psoriatic mouse model; IND for psoriasis expected in 2024.","May initiate Phase 2a studies in bipolar, MDD, and ADHD in H2 2023 subject to additional financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300992,"accession_number":"0001437749-23-011379","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Reviva grants stock options to CEO, CFO, and VP; 1.303M shares total","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Dr. Bhat granted option for 443,000 shares; CFO Prabhu for 170,000 shares.","VP Seema Bhat (CEO's spouse) granted option for 150,000 shares.","Options vest 50% immediately, then 1.389% monthly; exercise price $6.74.","Additional 540,000 options awarded to other employees under 2020 Plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320868,"accession_number":"0001437749-23-008498","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Reviva reports FY2022 net loss of $24.3M; cash runway through Q3 2023; Phase 3 topline data expected mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.3M ($1.25 per share) vs $8.5M ($0.58 per share) in FY2021.","Cash and equivalents $18.5M as of Dec 31, 2022, down from $29.7M; cash expected to fund operations through Q3 2023.","Over 50% of ~400 patients enrolled in pivotal Phase 3 RECOVER trial for brilaroxazine in schizophrenia; topline data expected mid-2023.","Completed majority of prelaunch studies for NDA submission; positive drug-drug interaction data reported.","May initiate Phase 2a studies in bipolar disorder, MDD, ADHD in H2 2023 subject to additional financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320867,"accession_number":"0001437749-23-000218","cik":1742927,"company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","ticker":"RVPH","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Reviva reports 40% enrollment in Phase 3 schizophrenia trial; top-line data expected mid-2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["About 40% of patients treated in pivotal Phase 3 RECOVER trial of brilaroxazine; no treatment-related SAEs.","Top-line data from Phase 3 trial expected mid-2023; NDA submission planned if positive, potential commercial launch in 2025.","Completed DDI study for brilaroxazine; results indicate advantage over other antipsychotics regarding drug interactions.","Raised $8.5M in September 2022 from registered direct offering and private placement; improved financial position.","Exploring non-dilutive financing and partnerships to expand brilaroxazine into bipolar, MDD, ADHD, PAH, IPF; combined market >$70B."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5413088.463345521,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-04T23:59:59+00:00|320867"}